Table 1.

Main features of included studies

Study year	n	Population	PCI	Follow-up	Intervention	Reference LD/MD	MACEs definitions	Major bleeding
Bhatt 2009	5362	NSTEMI: 60% UA: 35% SCAD: 5%	99%	30 days	Cangrelor IV 30 ug/kg bolus, 4 ug/kg/min 2-4 h, then clopidogrel then clopidogrel 600 mg	Placebo + clopidogrel 600 mg at the end of PCI	Death/MI/IDR	TIMI
Harrington 2009	8877	STEMI: 11% NSTEMI: 49% UA: 25% SCAD: 15%	100%	30 days	Cangrelor IV 30 mg/kg bolus and 4 mg/kg/min 2 h	Placebo + clopidogrel 600 mg 30 min before PCI	Death/MI/IDR	TIMI
Leonardi 2012	10900	STEMI: 0% NSTEMI: 57% UA: 31% SCAD: 12%	100%	48 h	Cangrelor IV 30 mg/kg bolus and 4 mg/kg/min 2-4 h	Placebo + clopidogrel 600 mg at the end of PCI	Death/MI/IDR	TIMI
Bhatt 2103	10942	STEMI: 18% NSTEMI: 26% SCAD: 56%	100%	48 h	Cangrelor IV 30 mg/kg bolus and 4 mg/kg/min 2-4 h	Clopidogrel 600 or 300 mg LD	Death/MI/IDR/ST	TIMI

PCI, percutaneous coronary intervention; NSTEMI, none ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; UA, unstable angina; SCAD, stable coronary artery disease; LD, loading dose; MD, maintenance dose; MACCE, major adverse cardiac and cerebrovascular events; IV: intravenous; MI: myocardical infarction; IDR, ischemia-driven revascularization; ST, stent thrombosis; TIMI, thrombolysis in myocardial infarction criteria.